Yezan Munther Haddadin, Director at Outlook Therapeutics, Inc. (OTLK), bought 10,000 shares at $1.39 ($14K) on 2021-12-02, disclosed to the SEC on 2021-12-02.
Open-market purchase of $14k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Clearly above the average filing.
| Filing → |
| OTLK | BUY | 2024-03-29 | $22K | — | Filing → |
| OTLK | BUY | 2022-10-11 | $43K | — | Filing → |
| OTLK | BUY | 2021-04-20 | $18K | — | Filing → |